CD8A and neoplasm: To determine whether the long-term immunity observed in INT-1B3-treated mice was T cell mediated, 4T1-challenged INT-1B3 survivor mice were treated with anti-CD4 and anti-CD8 antibodies before rechallenge with 4T1 tumor cells (Figure 2A).